Results 41 to 50 of about 445,769 (362)
BMJ, 2002 Bone marrow, or haematopoietic stem cell, transplants were originally developed to allow the use of very high dose treatments for malignancies such as leukaemia. Their use was based on the ideathat the high dose treatment might overcome inherent resistance of the malignancy to chemotherapy or radiotherapy. Transplants of stem cells from either the same
Johnson, Peter W. M., Orchard, Kim
openaire +4 more sources
FoxO1 signaling in B cell malignancies and its therapeutic targeting
FEBS Letters, EarlyView.FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac +3 more
wiley +1 more source
Journal of Interdisciplinary Medicine, 2017 Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder, which can involve the hematopoietic stem cell or early progenitor cells, without the loss of their capacity to differentiate.
Benedek István +6 more
doaj +1 more source
RCMNet: A deep learning model assists CAR-T therapy for leukemia [PDF]
arXiv, 2022 Acute leukemia is a type of blood cancer with a high mortality rate. Current therapeutic methods include bone marrow transplantation, supportive therapy, and chemotherapy. Although a satisfactory remission of the disease can be achieved, the risk of recurrence is still high. Therefore, novel treatments are demanding. Chimeric antigen receptor-T (CAR-T)
arxiv
FEBS Letters, EarlyView.Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects nearly one‐third of the global population and poses a significant risk of progression to cirrhosis or liver cancer. Here, we discuss the roles of hepatic dendritic cell subtypes in MASLD, highlighting their distinct contributions to disease initiation and progression, and their ...
Camilla Klaimi +3 more
wiley +1 more source
Leukemia with Plasma Cells — Case Report
Journal of Interdisciplinary Medicine, 2017 Plasma cell leukemia (PCL) is one of the most aggressive monoclonal gammopathies, being characterized by the presence of more than 20% of plasma cells in the peripheral blood and an absolute number of these cells of more than 2×109, with different ...
Benedek István +6 more
doaj +1 more source
Frontiers in Oncology, 2023 BackgroundPatients with refractory/relapsed (r/r) acute B lymphocytic leukemia (B-ALL) can achieve complete response (CR) after chimeric antigen receptor T-cell (CAR-T) therapy, but recurrence occurs in the short term.
Zhihui Li +11 more
doaj +1 more source
The power of microRNA regulation—insights into immunity and metabolism
FEBS Letters, EarlyView.MicroRNAs are emerging as crucial regulators at the intersection of metabolism and immunity. This review examines how miRNAs coordinate glucose and lipid metabolism while simultaneously modulating T‐cell development and immune responses. Moreover, it highlights how cutting‐edge artificial intelligence applications can identify miRNA biomarkers ...
Stefania Oliveto +2 more
wiley +1 more source
Clinical intestinal transplantation: New perspectives and immunologic considerations [PDF]
, 1998 Background: Although tacrolimus-based immunosuppression has made intestinal transplantation feasible, the risk of the requisite chronic high- dose treatment has inhibited the widespread use of these procedures.
Abu-Elmagd, K +14 more
core +1 more source
BMC Cancer, 2021 Background Isocitrate dehydrogenase (IDH1/2) gene mutations are the most frequently observed mutations in cartilaginous tumors. The mutant IDH causes elevation in the levels of R-enantiomer of 2-hydroxylglutarate (R-2HG). Mesenchymal stromal cells (MSCs)
Lizhen Liu +9 more
doaj +1 more source